Wedbush Predicts Higher Earnings for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a research report issued to clients and investors on Monday, December 23rd. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of $1.52 for the quarter, up from their prior estimate of $1.49. Wedbush has a “Outperform” rating and a $148.00 price target on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.94 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.82 EPS, Q3 2025 earnings at $1.90 EPS, Q4 2025 earnings at $2.46 EPS, FY2025 earnings at $7.71 EPS and FY2026 earnings at $10.87 EPS.

Other analysts also recently issued research reports about the stock. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. BMO Capital Markets dropped their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Raymond James restated an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $166.29.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $136.53 on Tuesday. The company has a market cap of $13.82 billion, a price-to-earnings ratio of 36.60 and a beta of 0.34. Neurocrine Biosciences has a 12 month low of $110.95 and a 12 month high of $157.98. The stock’s 50-day moving average is $124.79 and its 200-day moving average is $130.60.

Institutional Trading of Neurocrine Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of NBIX. Ashton Thomas Private Wealth LLC bought a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at about $28,000. Innealta Capital LLC acquired a new position in Neurocrine Biosciences in the second quarter valued at approximately $30,000. Blue Trust Inc. grew its holdings in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares during the last quarter. Plato Investment Management Ltd raised its position in shares of Neurocrine Biosciences by 44.1% during the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after purchasing an additional 130 shares during the period. Finally, Truvestments Capital LLC bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter worth approximately $63,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now owns 2,507 shares of the company’s stock, valued at $338,445. This trade represents a 30.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares of the company’s stock, valued at $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.